Session Coordinator:
Ângelo Cardoso / Technologists' Committee

Session Name: CTE 6
Tuesday, October 07th, 08:00 - 09:30

Session Title
Fibroblast-activated: the 68Ga-FAPI in different types of cancer

Chairpersons
Ozgul Ekmekcioglu (Istanbul, Turkey)
Paolo Turco (Padova, Italy)

Sample Programme

08:00 - 08:30	**Kim Pabst (Essen, Germany): Fibroblast Activation Protein – The Science Behind 68Ga-FAPI Imaging**
08:30 - 09:00	**Morten Bentestuen (Aalborg, Denmark): How to Perform FAPI PET?**
09:00 - 09:30	**Brittany Emmerson (Melbourne, Australia): 68Ga-FAPI Imaging – Practical Considerations for Technologists**

Educational Objectives
1. **To understand the principles of 68Ga-FAPI PET Imaging**
2. **To understand the Role of 68Ga-FAPI in Cancer Diagnosis**
3. **To compare 68Ga-FAPI with Traditional Imaging Techniques**
4. **To evaluate the Clinical Applications of 68Ga-FAPI in Cancer Treatment**
5. **To understand Potential Limitations and Challenges**
6. **To understand the Technologists Role in FAPI examinations**

Summary

68Ga-FAPI imaging refers to a type of PET (Positron Emission Tomography) imaging that uses a radiotracer called 68Gallium-labeled fibroblast activation protein inhibitor (68Ga-FAPI). This imaging technique targets fibroblast activation protein (FAP), which is highly expressed in the tumor microenvironment of many solid tumors.

In 68Ga-FAPI imaging, the 68Ga-FAPI radiotracer binds to FAP, allowing PET imaging to visualize the location and extent of tumors with high sensitivity and specificity. It has shown promise in detecting a variety of cancers, including pancreatic, ovarian, prostate, and colorectal cancers, among others.

Unlike traditional PET tracers like FDG (fluorodeoxyglucose), 68Ga-FAPI specifically targets the tumor microenvironment, providing potentially better imaging for certain tumor types. This makes 68Ga-FAPI an excellent tool for personalized medicine, allowing for more targeted and timely

therapeutic adjustments.

This technique is valuable not only for diagnosing cancer but also for assessing treatment response and detecting metastasis or recurrence. It is particularly useful in cancers where traditional imaging methods may have limitations in detecting small or metastatic lesions.

During this session, our speakers will provide in-depth insights into this promising radiotracer and its significant role in clinical practice.

Key Words

68Ga-FAPI; PET-CT Imaging; Clinical Applications; Technologists.

Affiliation of all chairpersons/speakers as it should be used for all EANM'25 congress publications:

Chairperson 1: Dr. Ozgul Ekmekcioglu, University of Health Sciences, Sisli Hamidiye Etfal Education and Research hospital, Department of Nuclear Medicine, Istanbul, ozgulek@gmail.com

Chairperson 2: Dr. Paolo Turco, University Hospital of Padova, Dept. of Nuclear Medicine, Padova, Italy, paolo.turco@aopd.veneto.it

Speaker 1: Dr. Med. Kim Pabst, University Hospital of Essen, Dept. of Nuclear Medicine, Essen, Germany, Kim.Pabst@uk-essen.de

Speaker 2: Dr. Morten Bentestuen, University Hospital of Aalborg, Dept. of Nuclear Medicine, Aalborg, Denmark, m.bentestuen@rn.dk

Speaker 3: Mrs. Brittany Emmerson, Peter MacCallum Cancer Center, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Melbourne, Australia, Brittany.Emmerson@petermac.org

Free Registrations & Reimbursement Entitlements

Every speaker of a Tech Track Session will receive a complimentary congress registration.

For each session one reimbursement can be requested by you (towards the EANM Office).
A reimbursement (max €1,750- for travel and accommodation) might be only granted to someone who is working outside the field of Nuclear Medicine.

In case you would like to apply for the reimbursement, please state the speaker's name and explain why he/she shall receive it. The Congress Chair will check and eventually approve the reimbursement. Only after her approval, the reimbursement can be confirmed by you towards the speaker.